Kymera Therapeutics (NASDAQ:KYMR) PT Raised to $56.00 at Oppenheimer

Kymera Therapeutics (NASDAQ:KYMR) had its price target raised by equities researchers at Oppenheimer from $52.00 to $56.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 15.01% from the stock’s current price.

Several other equities research analysts have also issued reports on KYMR. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a research report on Monday, August 26th. B. Riley upped their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, July 9th. HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of Kymera Therapeutics in a research note on Monday, June 17th. Leerink Partners reiterated an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Finally, Morgan Stanley raised their target price on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 14th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.00.

Kymera Therapeutics Price Performance

KYMR stock opened at $48.69 on Friday. The stock has a market capitalization of $2.99 billion, a P/E ratio of -19.40 and a beta of 2.22. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $53.27. The business has a 50-day moving average of $45.79 and a 200-day moving average of $39.35.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. The firm had revenue of $25.60 million during the quarter, compared to the consensus estimate of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The business’s revenue was up 55.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.67) EPS. Equities analysts expect that Kymera Therapeutics will post -2.87 EPS for the current year.

Insider Activity at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Bruce Booth sold 453,960 shares of the company’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the sale, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. Insiders sold 495,605 shares of company stock worth $19,303,364 in the last ninety days. 15.82% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors have recently modified their holdings of KYMR. Charles Schwab Investment Management Inc. raised its holdings in shares of Kymera Therapeutics by 1.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 306,692 shares of the company’s stock worth $7,808,000 after buying an additional 4,951 shares in the last quarter. Norges Bank acquired a new position in shares of Kymera Therapeutics during the 4th quarter worth $12,834,000. UBS Group AG raised its holdings in shares of Kymera Therapeutics by 84.6% during the 4th quarter. UBS Group AG now owns 300,463 shares of the company’s stock worth $7,650,000 after buying an additional 137,704 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of Kymera Therapeutics by 1.3% during the 4th quarter. TD Asset Management Inc now owns 186,482 shares of the company’s stock worth $4,748,000 after buying an additional 2,400 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Kymera Therapeutics during the 4th quarter worth $792,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.